OIG recommends price adjustment for four drugs
The Office of the Inspector General (OIG) found that the average sale price based on data reported to Medicare for 39 medications exceeded the average manufacturer price by at least 5%.
In the third of a series of studies, the Office of the Inspector General (OIG) found that the average sale price based on data reported to Medicare for 39 medications exceeded the average manufacturer price by at least 5% in the third quarter of 2006. Four of the drugs have exceeded AMPs by at least 5% in each of the three reports. As a result, OIG is recommending that CMS institute a price adjustment for the four medications, which were not specified. OIG estimates that adjusting the 39 medications would save the Medicare program $13 million.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
